Skip to content
MatchScript
Menu

Evidence review

Injections vs Oral or Sublingual GLP-1: Which to Pick

Injectable GLP-1s have the big trials behind them; oral and sublingual options trade some evidence for convenience. A measured guide to picking your format.

By The MatchScript Team, Matching & Recommendations Desk

Once you've chosen a molecule, the next fork is how you take it: a weekly injection or an oral/sublingual option. This isn't just a needle-versus-no-needle preference — the two formats differ in how much published evidence stands behind them. Here's a measured guide to picking the one that fits you.

Injections: the well-studied default The large weight-loss trials everyone cites all studied once-weekly injections. Semaglutide reached about 15% average body-weight loss in STEP-1[[cite:1]], tirzepatide hit the low-to-mid 20% range in SURMOUNT-1[[cite:2]], and a head-to-head diabetes trial, SURPASS-2, compared the two injectables directly[[cite:3]]. If you want the format with the strongest evidence base, injectable is the default. The downside is obvious — a weekly self-injection — but the needles are small, and most people adjust within a few weeks.

Oral and sublingual: convenience with a caveat Oral tablets and sublingual (under-the-tongue) drops appeal to people who are needle-averse or want something simpler to travel with. Many well-run providers offer them. The honest caveat: most oral and sublingual GLP-1 options available through compounding pharmacies do not have the same large, published weight-loss trials behind them as the injectable products, and compounded medications are not FDA-approved products[[cite:4]]. That doesn't make them a bad choice — it means you're trading some evidence certainty for convenience, so a transparent provider and clinician oversight matter even more.

How to weigh it Pick injectable if you want the format with the deepest published evidence and don't mind a weekly shot. Lean oral or sublingual if needle aversion is a genuine barrier to starting or staying consistent — a slightly less-studied format you'll actually stick with can beat a well-studied one you avoid. Consistency is what drives results, so be honest with yourself about what you'll keep doing.

Which providers offer what Most providers offer injectables; a smaller set adds oral or sublingual routes. [Vaylen](/reviews/vaylen) is notable for carrying injectable, oral, compounded, and brand in one place, so you can switch formats without switching providers. [ShedRx](/reviews/shedrx) is built around the oral/sublingual experience. See the full breakdown of who offers oral options in our [best GLP-1 provider by need](/best-glp1-provider-by-need) guide, or line providers up in the [comparison hub](/compare).

Still deciding? Take the quiz If format is your sticking point, the [2-minute quiz](/quiz) factors it in alongside budget and support, then reweights our honest [Match Score](/methodology) to surface providers that carry the route you want. And if you haven't locked in a molecule yet, start with [semaglutide vs tirzepatide](/semaglutide-vs-tirzepatide).

Frequently asked questions

Are oral GLP-1s as effective as injections?

The large published weight-loss trials all studied injectables. Most oral and sublingual options available through compounding pharmacies don't have the same trial evidence, so you're trading some evidence certainty for convenience. Clinician oversight and a transparent provider matter more if you choose them.

Do the injections hurt?

They use small needles and most people find them very tolerable, adjusting within a few weeks. Needle aversion is still a real barrier for some, which is where oral or sublingual options come in.

Which format should I pick?

Choose injectable for the strongest evidence base if you don't mind a weekly shot. Lean oral or sublingual if needle aversion would stop you from starting or staying consistent — the format you'll actually stick with wins.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  3. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
  4. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.